Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of metabolic reprogramming in drug resistance to epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences - 28 May 2021

Wu Yu, Gao Wei, Liu Hao

Abstract excerpt

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) can effectively inhibit the growth of EGFR-dependent mutant non-small cell lung cancer (NSCLC). Unfortunately, NSCLC patients often develop severe drug resistance after long-term EGFR-TKI treatment. Studies have shown that the disorder of energy metabolism in tumor cells can induce EGFR-TKI resistance. Due to the drug action, gene mutation and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Epidermal Growth Factor

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 34148892
DOI: 10.11817/j.issn.1672-7347.2021.200529
PMCID: PMC10930213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of metabolic reprogramming in drug resistance to epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.PMID 34148892Read ↗

Therapeutic strategies of metabolic reprogramming in non-small cell lung carcinoma.Semantic proximity Read ↗

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

NSCLC presents metabolic heterogeneity, and there is still some leeway for EGF stimuli in EGFR-mutated NSCLC.Semantic proximity Read ↗

Shining a light on metabolic vulnerabilities in non-small cell lung cancer.Semantic proximity Read ↗

The roles of glucose metabolic reprogramming in chemo- and radio-resistanceSemantic proximity Read ↗

Research progress of hyperthermia in tumor therapy by influencing metabolic reprogramming of tumor cellsSemantic proximity Read ↗

Metabolic reprogramming of carcinoma-associated fibroblasts and its impact on metabolic heterogeneity of tumors.Semantic proximity Read ↗

Oncogene-Driven Metabolic Alterations in CancerSemantic proximity Read ↗

Cancer Cell Metabolism Reprogramming and Its Potential Implications on Therapy in Squamous Cell Carcinoma of the Head and Neck: A ReviewSemantic proximity Read ↗

Role and therapeutic targeting of glutamine metabolism in non‑small cell lung cancer (Review)Semantic proximity Read ↗

Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung CancersSemantic proximity Read ↗

Metabolic Reprogramming in Hematologic Malignancies: Advances and Clinical PerspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.